135635-46-0

Usage

Uses

Used in Medicinal Chemistry:
(E)-17-ethyl-1,14-dihydroxy-12[(E)-2-(4-hydroxy-3-Methoxycyclohexyl)-1-Methylvinyl]-23,25-diMethoxy-13,19,21,27-tetraMethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(super4,9)]octacos-18-ene-2,3,10,16-tetrone is used as a compound of interest in medicinal chemistry for its potential diverse and significant biological activity. Its unique arrangement of functional groups may contribute to the development of new therapeutic agents.
Used in Drug Development:
In the field of drug development, (E)-17-ethyl-1,14-dihydroxy-12[(E)-2-(4-hydroxy-3-Methoxycyclohexyl)-1-Methylvinyl]-23,25-diMethoxy-13,19,21,27-tetraMethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(super4,9)]octacos-18-ene-2,3,10,16-tetrone is utilized as a starting point for the design and synthesis of novel pharmaceuticals. Its complex structure and functional groups offer opportunities for optimization and modification to enhance its therapeutic potential.
Used in Pharmaceutical Research:
(E)-17-ethyl-1,14-dihydroxy-12[(E)-2-(4-hydroxy-3-Methoxycyclohexyl)-1-Methylvinyl]-23,25-diMethoxy-13,19,21,27-tetraMethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(super4,9)]octacos-18-ene-2,3,10,16-tetrone is employed in pharmaceutical research to explore its potential as a lead compound for the treatment of various diseases. Its unique chemical structure and functional groups may provide insights into the development of new therapeutic agents with improved efficacy and selectivity.

Upstream product

• 668990-41-8 C₆₁H₁₁₃NO₁₃Si₃ 
• 668990-40-7 C₆₁H₁₁₁NO₁₂Si₃ 
• 668990-42-9 C₆₁H₁₁₃NO₁₂Si₃ 
• 273752-75-3 2(R),10(S),11(S)-cyclo-ascomycin 
• 671222-63-2 11-epi-ascomycin 
• 137071-45-5 24,33-bis-OTBDMS-ascomycin 

Downstream Products

• 133941-74-9 33-O-(tert-butyldimethylsilyl)-ascomycin 
• 143839-74-1 L 685818 
• 134226-79-2 33-(tert-butyldimethylsilyl)-24-deoxy-ascomycin 
• 233600-08-3 ascomycin hydrazone 
• 261759-01-7 17-but-1-enyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-21,23-dimethoxy-13,17,19,25-tetramethyl-11,26-dioxa-4-aza-tricyclo[20.3.1.0^4,9]hexacosane-2,3,10,16-tetraone 
• 261759-00-6 4-β-methoxy-9-dihydroascomycin 
• 649748-30-1 C₆₁H₁₁₁NO₁₂Si₃ 
• 649748-43-6 formic acid 17-ethyl-12-[2-(4-formyloxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-1-hydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo-11,28-dioxa-4-aza-tricyclo[22.3.1.0^4,9]octacos-18-en-14-yl ester 

Relevant academic research and scientific papers

METHOD OF PURIFYING MACROLIDES

A method for purifying macrolide is provided in which a loading charge of macrolide is placed in juxtaposition with a bed of wet sorption resin, the loading charge and bed are eluted at a temperature greater than 30°C with an eluent of an organic solvent selected from the group consisting of THF, acetonitrile, n-propyl alcohol, iso-propyl alcohol, ethyl alcohol, and acetone, the heart cut of the eluent is collected, and purified macrolide is collected.

METHOD OF PURIFYING MACROLIDES

Provided is a method of purifying a macrolide, especially tacrolimus, that includes loading macrolide onto a bed of sorption resin and elting with a suitable eluent such as a combination of water and tetrahydrofuran.

A PROCESS FOR THE RECOVERY OF SUBSTANTIALLY PURE TRICYCLIC MACROLIDE

Process for the recovery of a macrolide in substantially pure form comprising: a) treating the macrolide with water immiscible solvent followed by concentration, b) mixing with water, water miscible solvent or mixture thereof, c) performing hydrophobic interaction chromatography and collecting the fractions, d)extracting the fraction containing macrolide with water immiscible solvent followed by concentration, e) adding water miscible solvent to effect separation of impurities from the macrolide compound, f) performing silica gel chromatography and collecting the fractions, g) isolating the macrolide compound in substantially pure form. The macrolide is preferably rapamycin, tacrolimus or immunomycin.

CRYSTALLIZATION AND PURIFICATION OF MACROLIDES

Provided is a method for crystallization and purification of a macrolide such as tacrolimus, sirolimus, pimecrolimus, or everolimus that includes the step of providing a combination of a macrolide, and a polar solvent, dopolar aprotic solvent, or hydrocarbon solvent at pH of 7 or above.

Selective transformation of ascomycin into 11-epi-ascomycin

Within the binding domain, ascomycin features the unusual pattern of a masked tricarbonyl moiety, which potentially allows for high structural diversity via simple isomerisation events. A cascade of diastereoselective rearrangement reactions at the binding domain, allowing the conversion of ascomycin into 11-epi-ascomycin is herein reported.

Regio- and stereoselective preparation of ascomycin-d1 and FK 506-d1

The immunosuppressive macrolides ascomycin 1 and FK 506 2 were stereoselectively deuteriated at C(32) using Curran's radical translocating method. Both AIBN and Et3B/O2 were tested as radical initiator for the radical translocation/reduction step with Bu3SnD as reducing agent. Despite only minor structural differences, ascomycin and FK 506 showed remarkably different behaviour under the radical translocation/reduction conditions. Higher stereoselectivities were observed with Et3B/O2 as initiator, presumably due to lower reaction temperatures applied in this case. Copyright